The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1097
February 5, 2001
View Complete Issue         Table of Contents 2019 
Argatroban For Treatment of Heparin-Induced Thrombocytopenia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Argatroban For Treatment of Heparin-Induced Thrombocytopenia
February 5, 2001 (Issue: 1097)
Argatroban, a small-molecule synthetic derivative of L-arginine, is a direct thrombin inhibitor approved by the FDA for use as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Argatroban For Treatment of Heparin-Induced Thrombocytopenia
Article code: 1097b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.